

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4188528

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	NUNC PRO TUNC ASSIGNMENT
<b>EFFECTIVE DATE:</b>	06/13/2014
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
YOUJIN CHEN	12/07/2016
JIAN LIU	12/07/2016
YAPING MA	12/08/2016
JIANCHENG YUAN	12/08/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	HYBIO PHARMACEUTICAL CO., LTD.
<b>Street Address:</b>	4TH FLOOR OFFICE BUILDING, HYBIO MEDICINE PARK, MIDDLE ZONE HI-TECH INDUSTRIAL PARK
<b>Internal Address:</b>	NANSHAN DISTRICT
<b>City:</b>	SHENZHEN, GUANGDONG
<b>State/Country:</b>	CHINA
<b>Postal Code:</b>	518057
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15318356
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(323)934-0202
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(323) 934-2300
<b>Email:</b>	LA_MAIL@la.ladas.com
<b>Correspondent Name:</b>	LADAS & PARRY LLP
<b>Address Line 1:</b>	5670 WILSHIRE BLVD # 2100
<b>Address Line 4:</b>	LOS ANGELES, CALIFORNIA 90036
<b>ATTORNEY DOCKET NUMBER:</b>	B-9047PCT 630763-8
<b>NAME OF SUBMITTER:</b>	DAIFEI ZHANG
<b>SIGNATURE:</b>	/Daifei Zhang - L0733/
<b>DATE SIGNED:</b>	12/15/2016

**Total Attachments: 3**

source=630763\_Assignment#page1.tif

source=630763\_Assignment#page2.tif

source=630763\_Assignment#page3.tif

Assignment of CHEN, LIU, MA, and Yuan  
To Hybio Pharmaceutical Co., Ltd.

#### ASSIGNMENT

WHEREAS, we, Youjin CHEN, of Shenzhen, China, Jian LIU, of Shenzhen, China, Yaping MA, of Shenzhen, China, and Jiancheng YUAN, of Shenzhen, China, ("Assignor"), are the inventors of an invention entitled "GANIRELIX PRECURSOR AND METHOD FOR PREPARING GANIRELIX ACETATE BY USING THE SAME" that is the subject matter of: (check all that apply)

- ☒ a U.S. application for Letters Patent which claims the priority to Chinese Patent Application No. 201410265647.7 filed on June 13, 2014,
- ☒ an application made under the Patent Cooperation Treaty which is identifiable at WIPO by Application No. PCT/CN2015/081311 filed June 12, 2015,
- ☒ an application for Letters Patent which is identifiable in the Patent Office of the U.S. by Application No. 15/318.356 filed on Dec. 12, 2016 ;

WHEREAS, HYBIO PHARMACEUTICAL CO., LTD., a Corporation organized and existing under the laws of China ("Assignee"), and having offices at 4th Floor Office Building, Hybio Medicine Park, Middle Zone Hi-Tech Industrial Park, Nanshan District, Shenzhen, Guangdong 518057, China is desirous of acquiring the entire right, title and interest in and to the invention, the applications, and any and all Letters Patent or similar foreign or domestic legal protection

- ☒ in the United States
- ☐ in all other countries or jurisdictions;

"NOW THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged,

- a) I agree to transfer, and
- b) I do hereby transfer,

to Assignee, its successors and assigns, effective as of June 13, 2014, *nunc pro tunc*, our entire right, title and interest in the above-named countries and jurisdictions in and to the following including the right to sue for past infringement: the invention, the above-identified applications, all applications from which any of the above-identified applications claim priority, corresponding U.S. and non-U.S. applications, any continuation, continuation-in-part, division, renewal, and substitute for the applications, all Letters Patent, any reissue, re-examination, or similar legal protection issuing related to the Letters Patent, and all rights and benefits under any applicable treaty or convention, and we authorize the Director of the United States Patent and Trademark Office or foreign equivalent to issue the Letters Patent or similar legal protection to the Assignee.

We authorize the U.S. Attorneys handling the U.S. case for this matter and the Assignee, its successors and assigns, to insert in this instrument the filing date(s) and application numbers when ascertained. We further authorize the Assignee, its successors and assigns, or anyone it may properly designate, to apply for Letters Patent or similar legal protection, in its own name if desired, in the above-named countries and jurisdictions and appoint Assignee the common representative in the above-identified international application and any international application for the invention.

We represent to the Assignee, its successors and assigns, that we shall not execute any writing or do any act whatsoever conflicting with this Assignment. We, our executors or administrators, will at any time, upon request without additional consideration but at the expense of the Assignee, its successors and assigns, execute and deliver to Assignee or its legal representatives such additional writings and do such additional acts as the Assignee, its successors and assigns, may deem desirable to perfect its enjoyment of this grant, and render all assistance in making application for and obtaining, maintaining, and enforcing

Assignment of CHEN, LIU, MA, and Yuan  
To Hybio Pharmaceutical Co., Ltd.

the Letters Patent or similar legal protection on the invention in any and all countries and jurisdictions, including without limitation providing testimony in any related interference, litigation or proceeding. To the extent that we, our executors or administrators are unable or unavailable to execute and deliver to Assignee or its legal representatives such additional writings and do such additional acts as Assignee, its successors and assigns may deem desirable to perfect its enjoyment of this grant, and render all assistance in making application for and obtaining, maintaining, and enforcing the Letters Patent or similar legal protection on the invention in any and all countries and jurisdictions, we, our executors or administrators hereby authorize Assignee, its successors and assigns to act on our behalf.

If any provision(s) of this Assignment are held unenforceable or in conflict with the law of any jurisdiction, the validity of the remaining provisions will not be affected by such holding and the part held unenforceable in or in conflict with the law of one jurisdiction will remain in effect for other jurisdictions until held unenforceable or in conflict with the law of that jurisdiction.

Yujin chen

Yujin CHEN

(Inventor / Assignor)

2016.12.07

Date

~~~~~  
Jian LIU

Jian LIU

(Inventor / Assignor)

2016.12.07

Date

~~~~~  
Yaping Ma

Yaping MA

(Inventor / Assignor)

Dec-08-2016

Date

Assignment of CHEN, LIU, MA, and Yuan  
To Hybio Pharmaceutical Co., Ltd.



Jiancheng YUAN

(Inventor / Assignor)

Dec-08-2016

Date